An Audit to Evaluate the Clinical Safety and PSA Response of Firmagon® (Degarelix) in Patients with Advanced Metastatic Prostate Cancer -. J. Can. Res. Updates [Internet]. 2013 Jan. 14 [cited 2026 May 9];2(1): 21-25. Available from: https://www.neoplasiaresearch.com/index.php/jcru/article/view/398